BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kopylov U, Rosenfeld G, Bressler B, Seidman E. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:742-756. [PMID: 24562174 DOI: 10.1097/01.mib.0000442681.85545.31] [Cited by in Crossref: 99] [Cited by in F6Publishing: 37] [Article Influence: 14.1] [Reference Citation Analysis]
Number Citing Articles
1 Maréchal C, Aimone-Gastin I, Baumann C, Dirrenberger B, Guéant JL, Peyrin-Biroulet L. Compliance with the faecal calprotectin test in patients with inflammatory bowel disease. United European Gastroenterol J 2017;5:702-7. [PMID: 28815034 DOI: 10.1177/2050640616686517] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
2 Kopylov U, Klang E, Yablecovitch D, Lahat A, Avidan B, Neuman S, Levhar N, Greener T, Rozendorn N, Beytelman A, Yanai H, Dotan I, Chowers Y, Weiss B, Ben-Horin S, Amitai MM, Eliakim R; Israeli IBD research Nucleus (IIRN). Magnetic resonance enterography versus capsule endoscopy activity indices for quantification of small bowel inflammation in Crohn's disease. Therap Adv Gastroenterol. 2016;9:655-663. [PMID: 27582877 DOI: 10.1177/1756283x16649143] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
3 Guo X, Huang C, Xu J, Xu H, Liu L, Zhao H, Wang J, Huang W, Peng W, Chen Y, Nie Y, Zhou Y, Zhou Y. Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease. Front Nutr 2022;8:818902. [DOI: 10.3389/fnut.2021.818902] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Mahalhal A, Williams JM, Johnson S, Ellaby N, Duckworth CA, Burkitt MD, Liu X, Hold GL, Campbell BJ, Pritchard DM, Probert CS. Oral iron exacerbates colitis and influences the intestinal microbiome. PLoS One. 2018;13:e0202460. [PMID: 30308045 DOI: 10.1371/journal.pone.0202460] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
5 Barnes EL, Burakoff R. New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes. Inflamm Bowel Dis 2016;22:2956-65. [PMID: 27763951 DOI: 10.1097/MIB.0000000000000903] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
6 Kopylov U, Yablecovitch D, Lahat A, Neuman S, Levhar N, Greener T, Klang E, Rozendorn N, Amitai MM, Ben-Horin S, Eliakim R. Detection of Small Bowel Mucosal Healing and Deep Remission in Patients With Known Small Bowel Crohn's Disease Using Biomarkers, Capsule Endoscopy, and Imaging. Am J Gastroenterol. 2015;110:1316-1323. [PMID: 26215531 DOI: 10.1038/ajg.2015.221] [Cited by in Crossref: 86] [Cited by in F6Publishing: 85] [Article Influence: 12.3] [Reference Citation Analysis]
7 Yamamoto T. The clinical value of faecal calprotectin and lactoferrin measurement in postoperative Crohn’s disease. United European Gastroenterol J. 2015;3:5-10. [PMID: 25653853 DOI: 10.1177/2050640614558106] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
8 Boschetti G, Nancey S, Moussata D, Cotte E, Francois Y, Flourié B, Kaiserlian D. Enrichment of Circulating and Mucosal Cytotoxic CD8+ T Cells Is Associated with Postoperative Endoscopic Recurrence in Patients with Crohn's Disease. J Crohns Colitis 2016;10:338-45. [PMID: 26589954 DOI: 10.1093/ecco-jcc/jjv211] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
9 Carvalho A, Lu J, Francis JD, Moore RE, Haley KP, Doster RS, Townsend SD, Johnson JG, Damo SM, Gaddy JA. S100A12 in Digestive Diseases and Health: A Scoping Review. Gastroenterol Res Pract 2020;2020:2868373. [PMID: 32184815 DOI: 10.1155/2020/2868373] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
10 Greener T, Klang E, Yablecovitch D, Lahat A, Neuman S, Levhar N, Avidan B, Yanai H, Dotan I, Chowers Y, Weiss B, Saibil F, Amitai MM, Ben-Horin S, Kopylov U, Eliakim R; Israeli IBD Research Nucleus (IIRN). The Impact of Magnetic Resonance Enterography and Capsule Endoscopy on the Re-classification of Disease in Patients with Known Crohn's Disease: A Prospective Israeli IBD Research Nucleus (IIRN) Study. J Crohns Colitis. 2016;10:525-531. [PMID: 26748404 DOI: 10.1093/ecco-jcc/jjw006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 6.7] [Reference Citation Analysis]
11 Huang VW, Prosser C, Kroeker KI, Wang H, Shalapay C, Dhami N, Fedorak DK, Halloran B, Dieleman LA, Goodman KJ, Fedorak RN. Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy. Inflamm Bowel Dis 2015;21:1359-67. [PMID: 25989340 DOI: 10.1097/MIB.0000000000000376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
12 Lahat A, Veisman I. Capsule Endoscopy in Crohn's Disease-From a Relative Contraindication to Habitual Monitoring Tool. Diagnostics (Basel) 2021;11:1737. [PMID: 34679435 DOI: 10.3390/diagnostics11101737] [Reference Citation Analysis]
13 Yan W, Meihao W, Zihan S, Lingjie H, Haotian C, Qian C, Lianli S. Correlation Between Crohn Disease Activity and Serum Selenium Concentration. Clinical Therapeutics 2022. [DOI: 10.1016/j.clinthera.2022.03.005] [Reference Citation Analysis]
14 Swale A, Miyajima F, Roberts P, Hall A, Little M, Beadsworth MB, Beeching NJ, Kolamunnage-Dona R, Parry CM, Pirmohamed M. Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study. PLoS One 2014;9:e106118. [PMID: 25170963 DOI: 10.1371/journal.pone.0106118] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
15 Kwapisz L, Mosli M, Chande N, Yan B, Beaton M, Micsko J, Mennill PW, Barnett W, Bax K, Ponich T, Howard J, Tirolese A, Lannigan R, Gregor J. Rapid fecal calprotectin testing to assess for endoscopic disease activity in inflammatory bowel disease: A diagnostic cohort study. Saudi J Gastroenterol 2015;21:360-6. [PMID: 26655130 DOI: 10.4103/1319-3767.170948] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
16 Sjöberg F, Malipatlolla DK, Patel P, Wilderäng U, Kalm M, Steineck G, Bull C. Elastase as a potential biomarker for radiation-induced gut wall injury of the distal bowel in an experimental mouse model. Acta Oncol 2018;57:1025-30. [PMID: 29447028 DOI: 10.1080/0284186X.2018.1438652] [Reference Citation Analysis]
17 Bressler B, Panaccione R, Fedorak RN, Seidman EG. Clinicians’ guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease. Can J Gastroenterol Hepatol. 2015;29:369-372. [PMID: 26125109 DOI: 10.1155/2015/852723] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
18 Benítez JM, García-Sánchez V. Faecal calprotectin: Management in inflammatory bowel disease. World J Gastrointest Pathophysiol 2015; 6(4): 203-209 [PMID: 26600978 DOI: 10.4291/wjgp.v6.i4.203] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
19 Rosenfeld G, Greenup AJ, Round A, Takach O, Halparin L, Saadeddin A, Ho JK, Lee T, Enns R, Bressler B. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. World J Gastroenterol 2016; 22(36): 8211-8218 [PMID: 27688663 DOI: 10.3748/wjg.v22.i36.8211] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
20 Plevris N, Lees CW. Disease Monitoring in Inflammatory Bowel Disease: Evolving Principles and Possibilities. Gastroenterology 2022:S0016-5085(22)00078-6. [PMID: 35101422 DOI: 10.1053/j.gastro.2022.01.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Ollech JE, Bannon L, Maharshak N, Bar N, Goren I, Tulchinsky H, Yanai H, Dotan I. Fecal Calprotectin Is Increased in Pouchitis and Progressively Increases With More Severe Endoscopic and Histologic Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01224-6. [PMID: 34798336 DOI: 10.1016/j.cgh.2021.11.012] [Reference Citation Analysis]
22 Yamamoto T, Shimoyama T, Bamba T, Matsumoto K. Consecutive Monitoring of Fecal Calprotectin and Lactoferrin for the Early Diagnosis and Prediction of Pouchitis after Restorative Proctocolectomy for Ulcerative Colitis. Am J Gastroenterol. 2015;110:881-887. [PMID: 25916224 DOI: 10.1038/ajg.2015.129] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 4.9] [Reference Citation Analysis]
23 Shimoyama T, Yamamoto T, Umegae S, Matsumoto K. Faecal biomarkers for screening small bowel inflammation in patients with Crohn's disease: a prospective study. Therap Adv Gastroenterol 2017;10:577-87. [PMID: 28835772 DOI: 10.1177/1756283X17717683] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
24 Derkacz A, Olczyk P, Jura-Półtorak A, Olczyk K, Komosinska-Vassev K. The Diagnostic Usefulness of Circulating Profile of Extracellular Matrix Components: Sulfated Glycosaminoglycans (sGAG), Hyaluronan (HA) and Extracellular Part of Syndecan-1 (sCD138) in Patients with Crohn's Disease and Ulcerative Colitis. J Clin Med 2021;10:1722. [PMID: 33923501 DOI: 10.3390/jcm10081722] [Reference Citation Analysis]
25 Tham YS, Yung DE, Fay S, Yamamoto T, Ben-Horin S, Eliakim R, Koulaouzidis A, Kopylov U. Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn's disease: systematic review and meta-analysis. Therap Adv Gastroenterol 2018;11:1756284818785571. [PMID: 30034529 DOI: 10.1177/1756284818785571] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
26 Sajjadi M, Gholamrezaei A, Daryani NE. No association between serum adenosine deaminase activity and disease activity in Crohn's disease. Dig Dis Sci. 2015;60:1755-1760. [PMID: 25652144 DOI: 10.1007/s10620-014-3510-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
27 Archbald-Pannone LR. Quantitative Fecal Lactoferrin as a Biomarker for Severe Clostridium difficile Infection in Hospitalized Patients. J Geriatr Palliat Care 2014;2:3. [PMID: 25401164 DOI: 10.13188/2373-1133.1000006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
28 Kortman GA, Mulder ML, Richters TJ, Shanmugam NK, Trebicka E, Boekhorst J, Timmerman HM, Roelofs R, Wiegerinck ET, Laarakkers CM, Swinkels DW, Bolhuis A, Cherayil BJ, Tjalsma H. Low dietary iron intake restrains the intestinal inflammatory response and pathology of enteric infection by food-borne bacterial pathogens. Eur J Immunol 2015;45:2553-67. [PMID: 26046550 DOI: 10.1002/eji.201545642] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
29 Volarevic V, Zdravkovic N, Harrell CR, Arsenijevic N, Fellabaum C, Djonov V, Lukic ML, Simovic Markovic B. Galectin-3 Regulates Indoleamine-2,3-dioxygenase-Dependent Cross-Talk between Colon-Infiltrating Dendritic Cells and T Regulatory Cells and May Represent a Valuable Biomarker for Monitoring the Progression of Ulcerative Colitis. Cells 2019;8:E709. [PMID: 31336879 DOI: 10.3390/cells8070709] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
30 Mizoguchi E, Subramaniam R, Okada T, Mizoguchi A. A Review of Selected IBD Biomarkers: From Animal Models to Bedside. Diagnostics (Basel) 2021;11:207. [PMID: 33573291 DOI: 10.3390/diagnostics11020207] [Reference Citation Analysis]
31 Collins PD. Video capsule endoscopy in inflammatory bowel disease. World J Gastrointest Endosc 2016; 8(14): 477-488 [PMID: 27499830 DOI: 10.4253/wjge.v8.i14.477] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
32 Zhou XL, Xu W, Tang XX, Luo LS, Tu JF, Zhang CJ, Xu X, Wu QD, Pan WS. Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis. BMC Gastroenterol. 2014;14:121. [PMID: 25002150 DOI: 10.1186/1471-230x-14-121] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
33 Li D, Zeng Z, Yu T, Qin J, Wu J, Song JC, Zhou ZY, Yuan JP. Expression and clinical implication of S100A12 in gastric carcinoma. Tumour Biol 2016;37:6551-9. [PMID: 26638166 DOI: 10.1007/s13277-015-4460-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
34 Waljee AK, Lipson R, Wiitala WL, Zhang Y, Liu B, Zhu J, Wallace B, Govani SM, Stidham RW, Hayward R, Higgins PDR. Predicting Hospitalization and Outpatient Corticosteroid Use in Inflammatory Bowel Disease Patients Using Machine Learning. Inflamm Bowel Dis. 2017;24:45-53. [PMID: 29272474 DOI: 10.1093/ibd/izx007] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 12.0] [Reference Citation Analysis]
35 Fukunaga S, Kuwaki K, Mitsuyama K, Takedatsu H, Yoshioka S, Yamasaki H, Yamauchi R, Mori A, Kakuma T, Tsuruta O, Torimura T. Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization. Int J Mol Med 2018;41:107-18. [PMID: 29115397 DOI: 10.3892/ijmm.2017.3244] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
36 Lee JM, Jang JH, Ryu JH, Yoo J, Lee BI, Kim SJ, Oh EJ. A comparison of diagnostic performance between two quantitative rapid fecal calprotectin assays in detecting active inflammatory bowel disease. PLoS One 2021;16:e0255974. [PMID: 34383847 DOI: 10.1371/journal.pone.0255974] [Reference Citation Analysis]
37 Kyle BD, Agbor TA, Sharif S, Chauhan U, Marshall J, Halder SLS, Ip S, Khan WI. Fecal Calprotectin, CRP and Leucocytes in IBD Patients: Comparison of Biomarkers With Biopsy Results. J Can Assoc Gastroenterol 2021;4:84-90. [PMID: 33855266 DOI: 10.1093/jcag/gwaa009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Magro F, Lopes J, Borralho P, Lopes S, Coelho R, Cotter J, Castro FD, Sousa HT, Salgado M, Andrade P, Vieira AI, Figueiredo P, Caldeira P, Sousa A, Duarte MA, Ávila F, Silva J, Moleiro J, Mendes S, Giestas S, Ministro P, Sousa P, Gonçalves R, Gonçalves B, Oliveira A, Rosa I, Rodrigues M, Chagas C, Dias CC, Afonso J, Geboes K, Carneiro F; Portuguese IBD Study Group (GEDII). Comparison of different histological indexes in the assessment of UC activity and their accuracy regarding endoscopic outcomes and faecal calprotectin levels. Gut 2019;68:594-603. [PMID: 29437913 DOI: 10.1136/gutjnl-2017-315545] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 19.0] [Reference Citation Analysis]
39 Boschetti G, Laidet M, Moussata D, Stefanescu C, Roblin X, Phelip G, Cotte E, Passot G, Francois Y, Drai J. Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn’s Disease. Am J Gastroenterol. 2015;110:865-872. [PMID: 25781366 DOI: 10.1038/ajg.2015.30] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 11.3] [Reference Citation Analysis]
40 Nishikawa T, Nakamura M, Yamamura T, Maeda K, Sawada T, Mizutani Y, Ishikawa T, Furukawa K, Ohno E, Miyahara R, Kawashima H, Hirooka Y. Lewis Score on Capsule Endoscopy as a Predictor of the Risk for Crohn's Disease-Related Emergency Hospitalization and Clinical Relapse in Patients with Small Bowel Crohn's Disease. Gastroenterol Res Pract 2019;2019:4274257. [PMID: 30944562 DOI: 10.1155/2019/4274257] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
41 Pastor L, Langhorst J, Schröder D, Casellas A, Ruffer A, Carrillo J, Urrea V, Massora S, Mandomando I, Blanco J, Naniche D. Different pattern of stool and plasma gastrointestinal damage biomarkers during primary and chronic HIV infection. PLoS One 2019;14:e0218000. [PMID: 31185037 DOI: 10.1371/journal.pone.0218000] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
42 Barnes EL, Liew CC, Chao S, Burakoff R. Use of blood based biomarkers in the evaluation of Crohn’s disease and ulcerative colitis. World J Gastrointest Endosc 2015; 7(17): 1233-1237 [PMID: 26634038 DOI: 10.4253/wjge.v7.i17.1233] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
43 Gauss A, Geib T, Hinz U, Schaefert R, Zwickel P, Zawierucha A, Stremmel W, Klute L. Quality of Life Is Related to Fecal Calprotectin Concentrations in Colonic Crohn Disease and Ulcerative Colitis, but not in Ileal Crohn Disease. Medicine (Baltimore). 2016;95:e3477. [PMID: 27100452 DOI: 10.1097/md.0000000000003477] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
44 Kopylov U, Seidman E. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. Therap Adv Gastroenterol 2016;9:513-26. [PMID: 27366220 DOI: 10.1177/1756283X16638833] [Cited by in Crossref: 33] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]